CN111358750B - Medicinal composition for eyes and medical application thereof - Google Patents
Medicinal composition for eyes and medical application thereof Download PDFInfo
- Publication number
- CN111358750B CN111358750B CN201811588132.5A CN201811588132A CN111358750B CN 111358750 B CN111358750 B CN 111358750B CN 201811588132 A CN201811588132 A CN 201811588132A CN 111358750 B CN111358750 B CN 111358750B
- Authority
- CN
- China
- Prior art keywords
- weight
- ophthalmic
- average molecular
- parts
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
The invention belongs to the field of medicines, and relates to an ophthalmic medicinal composition, which comprises 1 part by weight of active medicinal component and 0.02-300 parts by weight of liquid matrix; wherein the active pharmaceutical ingredient is at least one selected from anti-tumor drugs, anti-inflammatory drugs, immunosuppressants, angiogenesis inhibitors and glaucoma treatment drugs, and the liquid matrix is at least one selected from polyethylene glycol polypropionate with the weight-average molecular weight of 300-2000, polyethylene glycol adipate with the weight-average molecular weight of 200-3000, polyethylene-adipate-1,2-propylene glycol ester with the weight-average molecular weight of 300-4000, 1,2-propylene glycol sebacate polyester with the weight-average molecular weight of 800-4000 and adipic acid neopentyl glycol polyester with the weight-average molecular weight of 800-3000. The invention relates to a medical application of the ophthalmic medicine composition. The ophthalmic pharmaceutical composition of the present invention can be injected into the eyes, slowly release the active pharmaceutical ingredient in the eyes for a long time, and can be degraded in the eyes.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to an ophthalmic medicinal composition and a medical application of the ophthalmic medicinal composition.
Background
Anatomically, the eyeball comprises an eyeball front section and an eyeball rear section, wherein the eyeball front section accounts for about 1/3, the eyeball front section consists of a cornea, a pupil, an iris, aqueous humor, a ciliary body and a crystalline lens, the eyeball rear section accounts for about 2/3, and the eyeball rear section consists of a vitreous body, a retina, yellow spots, optic nerves, a choroid and a sclera. Abnormalities in any part of the eyeball may cause eye diseases, among which, retinal phlebitis, diabetic retinopathy, proliferative vitreoretinopathy, choroidal neovascularization, age-related macular degeneration, cystoid macular edema, vitreous macular adhesion, macular hole and other eye diseases are the main causes of vision impairment. Currently, ocular surface administration and systemic administration are still the main administration modes for treating diseases of the posterior segment of the eye, but due to the existence of a tear barrier, a corneal barrier and a conjunctiva barrier, ocular surface administration hardly reaches the posterior segment of the eye, and the systemic administration needs large dose and multiple administrations to ensure that the amount of the medicament reaching the posterior segment of the eye meets the treatment requirement under the influence of blood-aqueous humor and blood-retina barrier. Based on the situation, in order to improve the amount of the medicine reaching the posterior segment of the eye, injection administration around the eye and intravitreal injection administration are gradually adopted, but most of the medicine has short half-life in the vitreous body, and the medicine amount in the vitreous body can be maintained to meet the treatment requirement by multiple injection administration, so that the pain is caused to a patient, the compliance of the patient is reduced, and the risk of intraocular infection is increased.
In order to solve the problems caused by multiple injections, sustained-release implants are clinically used for treating diseases of the posterior segment of the eye, and the sustained-release implants are divided into non-biodegradable types and biodegradable types according to materials. For example, in 1996, FDA approval was given to ganciclovir for the treatment of cytomegalovirus retinitis, developed by the company pSivida australia, who was marketed in the approval of the FDA, which uses non-biodegradable materials polyvinyl alcohol and ethylene vinyl acetate copolymer as controlled release materials, and in 2005, reiser, which was developed by the company mainly for the treatment of non-infectious uveitis, was marketed in the approval of the FDA, which uses non-biodegradable materials polyvinyl alcohol and silicone oil as controlled release materials. Since the non-biodegradable sustained-release implant cannot be degraded and needs to be taken out through a secondary operation, the biodegradable implant is produced in order to solve the problem. The common biodegradable slow-release materials comprise hydroxypropyl methylcellulose, polylactic acid, polyglycolic acid and polylactic acid-glycolic acid copolymer, and the typical products on the market are Surodex and Ozurdex of Allergan company, wherein the polylactic acid-glycolic acid copolymer and the hydroxypropyl methylcellulose are used as materials to prepare the dexamethasone implant, the dexamethasone implant can continuously release dexamethasone for 7-10 days and is used for diminishing inflammation after cataract surgery, and the dexamethasone implant is prepared from the polylactic acid-glycolic acid copolymer as a material to treat macular edema and uveitis. However, whether the implant is a non-biodegradable implant or a biodegradable implant, the implant is currently implanted into the eye through surgery or a special administration device (such as an Ozurdex with a special injection device), which is complicated in operation and causes pain to the patient.
There is a need for an ophthalmic drug which is simple in administration and has a sustained release effect.
Disclosure of Invention
The invention provides an ophthalmic pharmaceutical composition, which can be injected into eyes by injection, and the ophthalmic pharmaceutical composition can slowly release active pharmaceutical ingredients in the eyes for a long time and can be degraded in the eyes. On the basis, the invention also provides the medical application of the ophthalmic medicine composition.
The invention relates to a pharmaceutical composition for eyes, which comprises the following components:
1 part by weight of active pharmaceutical ingredient;
0.02 to 300 parts by weight (e.g., 0.1 part by weight, 0.5 part by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.4 parts by weight, 3 parts by weight, 4 parts by weight, 5 parts by weight, 6 parts by weight, 7 parts by weight, 9 parts by weight, 10 parts by weight, 13 parts by weight, 15 parts by weight, 17 parts by weight, 20 parts by weight, 30 parts by weight, 40 parts by weight, 50 parts by weight, 60 parts by weight, 70 parts by weight, 80 parts by weight, 90 parts by weight, 100 parts by weight, 110 parts by weight, 130 parts by weight, 150 parts by weight, 170 parts by weight, 200 parts by weight, 220 parts by weight, 240 parts by weight, 260 parts by weight, 280 parts by weight, 290 parts by weight) of the liquid base;
wherein the active pharmaceutical ingredient is selected from at least one of antineoplastic drugs, anti-inflammatory drugs, immunosuppressants, angiogenesis inhibitors and glaucoma treatment drugs; the liquid matrix is at least one selected from the group consisting of polyethylene glycol polypropionate with a weight average molecular weight of 300-2000, polyethylene glycol adipate with a weight average molecular weight of 200-3000 (e.g., 400-2000, 300, 2500, 2600), poly-adipic acid-1,2-propylene glycol ester with a weight average molecular weight of 300-4000 (e.g., 600-3000, 400, 500, 3500, 3800), 1,2-propylene glycol sebacate polyester with a weight average molecular weight of 800-4000, and adipic acid neopentyl glycol polyester with a weight average molecular weight of 800-3000.
In certain embodiments of the first aspect of the present invention, the liquid matrix is polyethylene glycol adipate having a weight average molecular weight of 200 to 3000.
In certain embodiments of the first aspect of the present invention, the liquid matrix is poly (adipic acid-1,2-propylene glycol) having a weight average molecular weight of 300 to 4000.
In some embodiments of the first aspect of the present invention, the liquid matrix is 0.05 to 260 parts by weight, preferably 0.08 to 260 parts by weight, more preferably 1 to 240 parts by weight, such as 0.1 parts by weight, 0.5 parts by weight, 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.4 parts by weight, 3 parts by weight, 4 parts by weight, 5 parts by weight, 6 parts by weight, 7 parts by weight, 9 parts by weight, 10 parts by weight, 13 parts by weight, 15 parts by weight, 17 parts by weight, 20 parts by weight, 30 parts by weight, 40 parts by weight, 50 parts by weight, 60 parts by weight, 70 parts by weight, 80 parts by weight, 90 parts by weight, 100 parts by weight, 110 parts by weight, 130 parts by weight, 150 parts by weight, 170 parts by weight, 200 parts by weight, 220 parts by weight, 240 parts by weight.
In certain embodiments of the first aspect of the present invention, the liquid matrix is polyethylene glycol adipate having a weight average molecular weight of 200 to 3000 (e.g., 400 to 2000, 300, 2500, 2700) and/or poly-1,2-propylene glycol adipate having a weight average molecular weight of 300 to 4000 (e.g., 600 to 3000, 400, 500, 3500, 3800).
In certain embodiments of the first aspect of the present invention, the liquid matrix is polyethylene adipate having a weight average molecular weight of 300 to 2500 and/or poly-adipate-1,2-propylene glycol having a weight average molecular weight of 400 to 3600.
In some embodiments of the first aspect of the present invention, the active pharmaceutical ingredient is selected from chlorambucil, melphalan, cyclophosphamide, ifosfamide, carmustine, lomustine, semustine, chlorourethrin, cisplatin, carboplatin, oxaliplatin, fluorouracil, mitoxantrone, irinotecan, topotecan, vinblastine, vincristine, vindesine, vinorelbine, etoposide, teniposide, taxol, docetaxel, bleomycin, methotrexate, gemcitabine, capecitabine, hydroxyurea, mitomycin, gefitinib, sunitinib, dexamethasone acetate, prednisone acetate, fluocinolone, fluocinonide, triamcinolone, methylprednisolone acetate propionate of methylprednisolone halobetasol propionate, cortisone, hydrocortisone, cyclosporine, rapamycin, tacrolimus, mycophenolic acid, tacrolimus, mizomycin, mizoribine, sulfasalazine, azathioprine, methotrexate, bevacizumab, ranibizumab, pegaptanib sodium, aflibercept, latanoprost, travoprost, bemetrel, bimatoprost, tafluprost, pilocarpine, atropine, hyoscyamine, betaxolol, metoprolol, bunolol, metipranolol, propranolol, timolol, benzfurolol, acetazolamide, dorzolamide, brinzolamide, apraclonidine, brimonidine, dipivefrine, duperprazole and pharmaceutically acceptable salts thereof.
In some embodiments of the first aspect of the present invention, the active pharmaceutical ingredient is selected from at least one of topotecan, paclitaxel, dexamethasone, triamcinolone acetonide, rapamycin, bevacizumab, latanoprost, and pharmaceutically acceptable salts thereof.
In some embodiments of the first aspect of the present invention, the ophthalmic pharmaceutical composition further comprises a pharmaceutically acceptable excipient and optionally water.
In some embodiments of the first aspect of the present invention, the ophthalmic pharmaceutical composition is an ophthalmic pharmaceutical formulation, preferably an ophthalmic pharmaceutical sustained release formulation, more preferably an ophthalmic pharmaceutical sustained release formulation for injection.
In the present invention, the antineoplastic agents include, but are not limited to chlorambucil, melphalan, cyclophosphamide, ifosfamide, carmustine, lomustine, semustine, chlorouramicin, cisplatin, carboplatin, oxaliplatin, fluorouracil, mitoxantrone, irinotecan, topotecan, vinblastine, vincristine, vindesine, vinorelbine, etoposide, teniposide, paclitaxel, docetaxel, bleomycin, methotrexate, gemcitabine, capecitabine, hydroxyurea, mitomycin, gefitinib, and sunitinib.
In the present invention, the anti-inflammatory drug includes but is not limited to dexamethasone, dexamethasone acetate, prednisone acetate, fluocinolone acetonide, triamcinolone acetonide, methylprednisolone ethylen-propionate, halobetasol propionate, cortisone, hydrocortisone.
In the present invention, immunosuppressants include, but are not limited to, cyclosporine, rapamycin, tacrolimus, mycophenolate mofetil, tacrolimus, mizolamycin, mizolazine, sulfasalazine, azathioprine, methotrexate.
In the present invention, the neovascularization inhibitors include, but are not limited to, bevacizumab, ranibizumab, pegaptanib sodium, and aflibercept.
In the present invention, glaucoma treatment drugs include, but are not limited to, latanoprost, travoprost, bemetrostaglandin, bimatoprost, tafluprost, pilocarpine, atropine, hyoscyamine, betaxolol, metoprolol, bunolol, metipranolol, propranolol, timolol, benzofurol, acetazolamide, dorzolamide, brinzolamide, alaclonidine, brimonidine, dipivefrin, guanethidine, and dapipropane.
The second aspect of the present invention relates to a process for the preparation of an ophthalmic pharmaceutical composition according to the first aspect of the present invention, comprising the steps of:
mixing the active pharmaceutical ingredient, the liquid matrix, optionally pharmaceutically acceptable excipients and optionally water.
In some embodiments of the second aspect of the invention, the active pharmaceutical ingredient, liquid matrix, is an active pharmaceutical ingredient, liquid matrix as described in the first aspect of the invention.
In some embodiments of the second aspect of the invention, the pharmaceutically acceptable excipient is a pharmaceutically acceptable excipient as described in the first aspect of the invention.
A third aspect of the invention relates to an ophthalmic kit comprising an active pharmaceutical ingredient and a liquid base each separately packaged;
wherein the active pharmaceutical ingredient is selected from at least one of antineoplastic drugs, anti-inflammatory drugs, immunosuppressants, angiogenesis inhibitors and glaucoma treatment drugs; the liquid matrix is at least one of polyethylene glycol polypropionate with the weight-average molecular weight of 300-2000, polyethylene glycol adipate with the weight-average molecular weight of 200-3000 (such as 400-2000, 300, 2500 and 2600), poly-adipic acid-1,2-propylene glycol ester with the weight-average molecular weight of 300-4000 (such as 600-3000, 400, 500, 3500 and 3800), 1,2-propylene glycol sebacic acid polyester with the weight-average molecular weight of 800-4000 and adipic acid neopentyl glycol polyester with the weight-average molecular weight of 800-3000.
In some embodiments of the third aspect of the present invention, the liquid matrix is polyethylene glycol adipate having a weight average molecular weight of 200 to 3000 and/or poly-adipate-1,2-propylene glycol ester having a weight average molecular weight of 300 to 4000.
In some embodiments of the third aspect of the present invention, the liquid matrix is polyethylene glycol adipate having a weight average molecular weight of 300 to 2500 and/or poly-adipate-1,2-propylene glycol ester having a weight average molecular weight of 400 to 3600.
In some embodiments of the third aspect of the present invention, the liquid matrix is polyethylene glycol adipate having a weight average molecular weight of 200 to 3000.
In some embodiments of the third aspect of the present invention, the liquid matrix is poly (adipic acid-1,2-propylene glycol ester) having a weight average molecular weight of 300 to 4000.
In some embodiments of the third aspect of the invention, the ophthalmic kit comprises one or more of the following a to d:
a. the ophthalmic kit further comprises a syringe, preferably a pre-filled syringe;
b. the ophthalmic medicine box is used for injection;
c. the active pharmaceutical ingredient is selected from chlorambucil, melphalan, cyclophosphamide, ifosfamide, carmustine, lomustine, semustine, chlorourethrin, cisplatin, carboplatin, oxaliplatin, fluorouracil, mitoxantrone, irinotecan, topotecan, vinblastine, vincristine, vindesine, vinorelbine, etoposide, teniposide, taxol, docetaxel, bleomycin, methotrexate, gemcitabine, capecitabine, hydroxyurea, mitomycin, gefitinib, sunitinib, dexamethasone acetate, prednisone acetate, fluocinolone, fluocinonide, triamcinolone acetonide, methylprednisolone acetate propionate, betasol propionate halide, nedocosanol propionate at least one of cortisone, hydrocortisone, cyclosporine, rapamycin, tacrolimus, mycophenolic acid, tacrolimus, mizolamycin, mizolazine, sulfasalazine, azathioprine, methotrexate, bevacizumab, ranibizumab, pegaptanib sodium, aflibercept, latanoprost, travoprost, bemetprost, bimatoprost, tafluprost, pilocarpine, atropine, hyoscyamine, betaxolol, metoprolol, bunolol, metipranolol, propranolol, timolol, benzofurol, acetazolamide, dorzolamide, brinzolamide, apraclonidine, brimonidine, dipivefrine, dapiprazole, and pharmaceutically acceptable salts thereof;
preferably, the active pharmaceutical ingredient is selected from at least one of topotecan, paclitaxel, dexamethasone, triamcinolone acetonide, rapamycin, bevacizumab, latanoprost, and pharmaceutically acceptable salts thereof;
d. the ophthalmic kit further comprises an independently packaged pharmaceutically acceptable adjuvant and optionally water.
The fourth aspect of the present invention relates to the use of an ophthalmic pharmaceutical composition according to the first aspect of the present invention or an ophthalmic kit according to the third aspect of the present invention for the preparation of a medicament for the prevention and/or treatment of an ocular disease.
In some embodiments of the fourth aspect of the present invention, the ocular disease is a posterior segment of the eye disease.
In some embodiments of the fourth aspect of the present invention, the ocular disease is selected from at least one of glaucoma, uveitis, retinal vein occlusion, retinal artery occlusion, diabetic retinopathy, retinal phlebitis, proliferative vitreoretinopathy, choroidal neovascularization, cystoid macular edema, age-related macular degeneration, vitreous macular adhesion, macular hole, optic neuritis, optic disc edema, optic neuromeningioma, optic glioma, retinoblastoma, and choroidoblastoma.
In the present invention, unless otherwise specified,
the term "matrix" refers to a substance that does not react with the active pharmaceutical ingredient and contributes to the action of the active pharmaceutical ingredient, e.g., a substance that affects the administration, release, penetration, absorption of the active pharmaceutical ingredient, a substance that can shape the active pharmaceutical ingredient, and the like.
The term "liquid matrix" refers to a matrix that is liquid at ordinary temperature.
Advantageous effects of the invention
1. The ophthalmic pharmaceutical composition of the present invention can be injected into the eye by injection and can slowly release the active pharmaceutical ingredient in the eye for a long time.
2. The ophthalmic pharmaceutical composition of the present invention is degradable in the eye.
3. The ophthalmic medicine composition has good stability.
4. The ophthalmic medicine box can be used for preparing the medicine on site for use, and the shelf life of the medicine is prolonged.
Drawings
FIG. 1 is a graph showing the in vitro release rates of the drugs of ophthalmic preparation 9 and ophthalmic preparation A in Experimental example 3;
FIG. 2 is a graph showing the amount of the ophthalmic preparation 9 released into the vitreous of rabbit eyes in Experimental example 6.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
The materials used in the following preparations and comparative examples are as follows:
poly (adipic acid) -1,2-propylene glycol ester: the weight average molecular weight is 600-3000;
polyethylene glycol adipate: the weight average molecular weight is 400-2000.
Preparation examples 1-8 preparation of ophthalmic preparations 1-8
Weighing the liquid matrix and the active pharmaceutical ingredients according to the formula in the table 1, and uniformly stirring in a beaker to obtain a mixture; filling the mixture into pre-filled syringes, wherein the filling amount of each syringe is 0.1mL, and obtaining 1-8 ophthalmic preparations.
TABLE 1
Preparation example 9 preparation of ophthalmic preparation 9
2.5g of dexamethasone is weighed, 7.5g of poly adipic acid-1,2-propylene glycol ester is added into the dexamethasone and evenly mixed to obtain the ophthalmic preparation 9.
Preparation example 10 preparation of ophthalmic preparation 10
Weighing 20.0g of poly adipic acid-1,2-propylene glycol ester, adding 0.1g of latanoprost, uniformly mixing, and filling the mixture into a pre-filled and sealed syringe to obtain the ophthalmic preparation 10.
Preparation examples 11 to 14 preparation of ophthalmic preparations 11 to 14
The active pharmaceutical ingredient was mixed with the liquid base uniformly according to the formulation in table 2 to obtain ophthalmic preparations 11-14.
TABLE 2
Comparative example
2.5g of dexamethasone is weighed, 7.5g of triacetin is added into the dexamethasone and mixed evenly to obtain the ophthalmic preparation A.
Experimental example 1 stability of appearance of ophthalmic preparation
The ophthalmic preparation 1-8 is placed under the conditions of 40 ℃ +/-2 ℃ and relative humidity of 75% +/-5% for 6 months, and the change of the appearance of the preparation is observed.
As a result, it was found that the appearance of the ophthalmic preparations 1 to 8 after the placement was not changed from that before the placement.
Experimental example 2 Observation of ophthalmic preparation in phosphate buffer solution
The ophthalmic preparation 9 was injected into a beaker containing a phosphate buffer solution of pH =7.4 and osmotic pressure =292mOsmol/kg, and the presence state of the ophthalmic preparation in the phosphate buffer solution was observed.
As a result, it was found that the ophthalmic formulation 9 automatically aggregated into a spherical shape in a phosphate buffer solution, and deposited on the bottom of the beaker.
Experimental example 3 examination of in vitro Release degree of ophthalmic preparation
50 μ L each of ophthalmic formulation 9 and ophthalmic formulation a was injected into a beaker containing 150mL of release medium (phosphate buffer, containing 0.01% benzalkonium chloride, pH =7.4, osmolality =292 mOsmol/kg), the beaker was placed in an air bath shaker at a controlled temperature of 37 ± 0.5 ℃ and 1mL of release medium was aspirated at different times while supplemented with equal amounts of blank release medium. Filtering the absorbed release medium through a 0.22 μm microporous filter membrane, and determining the content of dexamethasone in the release medium by High Performance Liquid Chromatography (HPLC).
Liquid chromatography measurement conditions: an Ultimate, XB-C18 chromatography column (4.6X 250mm,5 μm); mobile phase: acetonitrile-water (40; detection wavelength: 240nm; column temperature: 30 ℃; flow rate: 1.0 mL/min -1 (ii) a Sample introduction amount: 20 μ L.
The cumulative release amount Rn% of the drug was calculated according to the following formula, and the results are shown in fig. 1.
Wherein, V 0 To release the volume of medium, C n Concentration at the time of the n-th sampling, V is the volume of the released medium taken up, M t Is the total drug concentration.
As can be seen from the observation of figure 1, the ophthalmic preparation of the invention can reduce the sustained-release rate of the ophthalmic preparation and achieve the effect of sustained release for about 200 days after one-time administration. When triacetin is used as the liquid base, the sustained release can be achieved only for about 120 days after one-time administration.
Experimental example 4 Observation of the appearance of ophthalmic preparation after injection into anterior chamber of rabbit eye
mu.L of ophthalmic formulation 10 was injected into the anterior chamber of rabbit eyes and changes in the formulation in the rabbit eyes were observed every other day using a hand held slit lamp.
The results show that after injection, the formulation aggregates into spheroidal droplets and gradually settles to the lower part of the anterior chamber; the drop volume gradually decreased with time, and the drop disappeared completely between days 108 and 122. This initially indicates that the ophthalmic formulations of the present invention can be slowly degraded in vivo, releasing the active pharmaceutical ingredient continuously.
Experimental example 5 Observation of ophthalmic preparation injected into vitreous body of rabbit eyeChange in appearance
25 μ L of ophthalmic preparation 11-14, 15 μ L of ophthalmic preparation 11, and 50 μ L of ophthalmic preparation 11 were injected into the vitreous humor of rabbit eyes, and the change of the preparations in the vitreous humor of rabbit eyes was observed every other day by using a hand-held slit lamp, and the results are shown in table 3.
TABLE 3
As can be seen from Table 3, the ophthalmic formulation of the present invention can be gradually degraded in the vitreous of rabbit eye, and the degradation time is positively correlated to the injection dosage.
Experimental example 6 pharmacokinetic study of a single intravitreal injection of ophthalmic formulations in Rabbit eyes
42 New Zealand rabbits were selected, three were combined into one group, 50. Mu.L of the ophthalmic preparation 9 was injected into the right eye of each group of rabbits, the same volume of poly (adipic acid-1,2-propylene glycol) was injected into the left eye, and one group of animals was sacrificed at a designated time, and the vitreous body was removed.
The cumulative release amount-time graph obtained by measuring the content of dexamethasone in the vitreous body by the HPLC method according to the method in experimental example 3 and calculating the cumulative release amount is shown in fig. 2.
Fig. 2 shows that the active pharmaceutical ingredient is slowly released in the vitreous of rabbit eyes, the drug release time is up to 336 days, and the release rate of the active pharmaceutical ingredient is uniform.
Although specific embodiments of the invention have been described in detail, those skilled in the art will appreciate. Many modifications and variations of those details may be made in light of the overall teachings of the disclosure, and such variations are within the scope of the invention. The full scope of the invention is given by the appended claims and any equivalents thereof.
Claims (13)
1. An ophthalmic pharmaceutical composition comprising the following components:
1 part by weight of active pharmaceutical ingredient;
0.1 to 300 parts by weight of a liquid matrix;
wherein the active pharmaceutical ingredient is selected from at least one of topotecan, paclitaxel, dexamethasone, triamcinolone acetonide, rapamycin, bevacizumab, latanoprost, and pharmaceutically acceptable salts thereof; the liquid matrix is at least one of polyethylene glycol adipate with the weight-average molecular weight of 200 to 3000 and polyethylene glycol adipate-1,2-propylene glycol ester with the weight-average molecular weight of 300 to 4000.
2. The ophthalmic pharmaceutical composition of claim 1, wherein the liquid matrix is 0.5 to 260 parts by weight.
3. The ophthalmic pharmaceutical composition of claim 1 or 2, wherein the liquid matrix is polyethylene glycol adipate with a weight average molecular weight of 300 to 2500 and/or polyethylene glycol adipate-1,2-propylene glycol ester with a weight average molecular weight of 400 to 3600.
4. The ophthalmic pharmaceutical composition according to claim 1 or 2, further comprising a pharmaceutically acceptable adjuvant and optionally water.
5. The ophthalmic pharmaceutical composition according to claim 1 or 2, which is an ophthalmic pharmaceutical preparation.
6. The ophthalmic pharmaceutical composition of claim 1, wherein the liquid matrix is 1 to 260 parts by weight.
7. The ophthalmic pharmaceutical composition according to claim 1 or 2, which is an ophthalmic sustained release pharmaceutical formulation.
8. The ophthalmic pharmaceutical composition according to claim 1 or 2, which is an injectable ophthalmic sustained-release pharmaceutical preparation.
9. A process for the preparation of an ophthalmic pharmaceutical composition according to any one of claims 1 to 8, comprising the steps of:
mixing the active pharmaceutical ingredient, the liquid base, optionally pharmaceutically acceptable excipients and optionally water.
10. An ophthalmic kit comprising an active pharmaceutical ingredient and a liquid base each separately packaged;
wherein the active pharmaceutical ingredient is selected from at least one of topotecan, paclitaxel, dexamethasone, triamcinolone acetonide, rapamycin, bevacizumab, latanoprost, and pharmaceutically acceptable salts thereof; the liquid matrix is at least one of polyethylene glycol adipate with the weight-average molecular weight of 200 to 3000 and polyethylene glycol adipate-1,2-propylene glycol ester with the weight-average molecular weight of 300 to 4000;
wherein the liquid matrix accounts for 0.1 to 300 parts by weight relative to 1 part by weight of the active pharmaceutical ingredient.
11. The ophthalmic kit of claim 10, comprising one or more of the following a to c:
a. the ophthalmic kit further comprises a syringe;
b. the ophthalmic medicine box is an ophthalmic medicine box for injection;
c. the ophthalmic kit further comprises an independently packaged pharmaceutically acceptable adjuvant and optionally water.
12. The ophthalmic kit of claim 11, wherein the syringe is a pre-filled syringe.
13. Use of an ophthalmic pharmaceutical composition according to any one of claims 1 to 8 or an ophthalmic kit according to any one of claims 10 to 12 for the preparation of a medicament for the prevention and/or treatment of an ocular disease;
the ocular disease is selected from at least one of glaucoma, uveitis, retinal vein occlusion, retinal artery occlusion, diabetic retinopathy, retinal phlebitis, proliferative vitreoretinopathy, choroidal neovascularization, cystoid macular edema, age-related macular degeneration, vitreous macular adhesions, macular holes, optic neuritis, optic disc edema, optic neuromeningioma, optic glioma, retinoblastoma, and choroidoblastoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811588132.5A CN111358750B (en) | 2018-12-25 | 2018-12-25 | Medicinal composition for eyes and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811588132.5A CN111358750B (en) | 2018-12-25 | 2018-12-25 | Medicinal composition for eyes and medical application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111358750A CN111358750A (en) | 2020-07-03 |
| CN111358750B true CN111358750B (en) | 2023-03-07 |
Family
ID=71198084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811588132.5A Active CN111358750B (en) | 2018-12-25 | 2018-12-25 | Medicinal composition for eyes and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111358750B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101553206A (en) * | 2006-11-09 | 2009-10-07 | 爱尔康研究有限公司 | Water insoluble polymer matrix for drug delivery |
| CN107595765A (en) * | 2017-09-22 | 2018-01-19 | 沈阳兴齐眼药股份有限公司 | A kind of ophthalmically acceptable sustained release drug delivery system and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
-
2018
- 2018-12-25 CN CN201811588132.5A patent/CN111358750B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101553206A (en) * | 2006-11-09 | 2009-10-07 | 爱尔康研究有限公司 | Water insoluble polymer matrix for drug delivery |
| CN107595765A (en) * | 2017-09-22 | 2018-01-19 | 沈阳兴齐眼药股份有限公司 | A kind of ophthalmically acceptable sustained release drug delivery system and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111358750A (en) | 2020-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5696121B2 (en) | Biodegradable intraocular implant containing α-2 adrenergic receptor agonist | |
| US10881609B2 (en) | Methods for treating eye disorders using ocular implants | |
| JP5485314B2 (en) | Steroid intraocular implant that provides long-term sustained release for more than 2 months | |
| JP6570513B2 (en) | Microsphere drug delivery system for sustained intraocular release | |
| CN109549918B (en) | Ophthalmic medicine composition, ophthalmic medicine box and medical application thereof | |
| JP6602761B2 (en) | Ophthalmic device | |
| CN107184544A (en) | Sustained-release therapeutic medicine implant in anterior chamber | |
| JP2007535367A (en) | Sustained release intraocular implants containing estradiol derivatives or estratopone derivatives, and related manufacturing methods | |
| CN111358750B (en) | Medicinal composition for eyes and medical application thereof | |
| CN111358751B (en) | Ophthalmic pharmaceutical composition, ophthalmic kit and medical application thereof | |
| Herrero-Vanrell et al. | Ocular pharmacokinetic drug, bioavailability and intraocular drug delivery systems | |
| CN112423740A (en) | Eye drop formulations and methods for sustained drug delivery to the retina | |
| Suresh et al. | Ocular implants as drug delivery device in opthalmic therapeutics: An overview |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 25, New Canal Road, Shenyang Area, China (Liaoning) Pilot Free Trade Zone, Hunnan District, Shenyang, Liaoning 110167 Patentee after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: 110163 Surabaya street, Dongling District, Shenyang, Liaoning Province, No. 68 Patentee before: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder |